In total, 50 million Europeans are affected by allergic diseases such as asthma and atopic dermatitis. Approximately 10% of these patients suffer from uncontrolled disease despite high dosages of treatment. Some patients might benefit from novel targeted, yet expensive and burdensome treatments. However, it remains unclear which patient will benefit from which type of treatment. Clinical tools to guide treatment based on individual profiles are lacking and studies including young patients are scarce. The PERMEABLE consortium aims to develop the urgently needed personalized medicine approach to tailor treatment in allergy and asthma in young patients, by combining preclinical and clinical research approaches, as well as applying innovative ICT solutions.
